Relevant bibliographies by topics / Antitumour

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Antitumour'

Author: Grafiati
Published: 4 June 2021
Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antitumour.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antitumour"

1

Sreco-Zelenovic, Bojana, Sanja Grabez, Mirjana Popsavin, Vesna Kojic, Jovana Francuz, and Velimir Popsavin. "Synthesis and antiproliferative activity of simplified goniofufurone analogues." Journal of the Serbian Chemical Society, no. 00 (2020): 56. http://dx.doi.org/10.2298/jsc200730056s.

Full text
Abstract:
Several (+)-goniofufurone analogues with simplified structures were designed, synthesized and evaluated for their in vitro antitumour activity against a panel of human tumour cell lines. Dephenylated compounds 2 and 3, demonstrated remarkable antitumour activities, in the cultures of K562 and Raji cells with IC50 values in the range of 3.0-9.3 nM. Each of goniofufurone analogues lacking the tetrahydrofuran ring (4, 5 and 6) strongly inhibited the growth of at least one malignant cell line, with IC50 values in the range of 11-30 nM. Brief SAR analysis showed that the simplified goniofufurone an
APA, Harvard, Vancouver, ISO, and other styles
2

Asche, C. "Antitumour Quinones." Mini-Reviews in Medicinal Chemistry 5, no. 5 (2005): 449–67. http://dx.doi.org/10.2174/1389557053765556.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Demeunynck, Martine. "Antitumour acridines." Expert Opinion on Therapeutic Patents 14, no. 1 (2004): 55–70. http://dx.doi.org/10.1517/13543776.14.1.55.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Slack, J. A., and C. Goddard. "Antitumour imidazotetrazines." Journal of Chromatography B: Biomedical Sciences and Applications 337 (January 1985): 178–81. http://dx.doi.org/10.1016/0378-4347(85)80027-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jones, Bryony. "Evading antitumour immunity." Nature Reviews Cancer 16, no. 7 (2016): 410. http://dx.doi.org/10.1038/nrc.2016.65.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jones, Bryony. "Evading antitumour immunity." Nature Reviews Genetics 17, no. 7 (2016): 374. http://dx.doi.org/10.1038/nrg.2016.77.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mitra, Roshni, Sarvjeet Singh, and Ashok Khar. "Antitumour immune responses." Expert Reviews in Molecular Medicine 5, no. 3 (2003): 1–22. http://dx.doi.org/10.1017/s1462399403005623.

Full text
Abstract:
The role of the immune system in combating tumour progression has been studied extensively. The two branches of the immune response – humoral and cell-mediated – act both independently and in concert to combat tumour progression, the success of which depends on the immunogenicity of the tumour cells. The immune system discriminates between transformed cells and normal cells by virtue of the presence of unique antigens on tumour cells. Despite this, the immune system is not always able to detect and kill cancerous cells because neoplasms have also evolved various strategies to escape immune sur
APA, Harvard, Vancouver, ISO, and other styles
8

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 1 (2003): 47–50. http://dx.doi.org/10.1016/s1359-6446(02)02551-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Westwell, Andrew D. "Novel antitumour molecules." Drug Discovery Today 8, no. 5 (2003): 229–31. http://dx.doi.org/10.1016/s1359-6446(03)02622-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Westwell, A. "Novel antitumour molecules." Drug Discovery Today 8, no. 9 (2003): 421–22. http://dx.doi.org/10.1016/s1359-6446(03)02676-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antitumour"

1

Mokdsi, George. "Antitumour Metallocenes." Thesis, The University of Sydney, 2000. http://hdl.handle.net/2123/794.

Full text
Abstract:
This thesis reports a study of the chemical stability and coordination chemistry of several antitumour metallocenes Cp2MCl2 (Cp = h5-C5H5; M = Ti 1, V 2, Nb 3, Mo 4), as well as derivatives of Cp2TiCl2 1, with nucleic acids, nucleic acid constituents and proteins. These studies were carried out in order to identify the biologically active species and more fully understand the molecular level mechanism of action of the antitumour metallocenes, in particular Cp2TiCl2 1, which is currently undergoing phase II clinical trials. The interactions of Cp2MoCl2 4 with four oligonucleotides were stud
APA, Harvard, Vancouver, ISO, and other styles
2

Mokdsi, George. "Antitumour Metallocenes." University of Sydney. Chemistry, 2000. http://hdl.handle.net/2123/794.

Full text
Abstract:
This thesis reports a study of the chemical stability and coordination chemistry of several antitumour metallocenes Cp2MCl2 (Cp = h5-C5H5; M = Ti 1, V 2, Nb 3, Mo 4), as well as derivatives of Cp2TiCl2 1, with nucleic acids, nucleic acid constituents and proteins. These studies were carried out in order to identify the biologically active species and more fully understand the molecular level mechanism of action of the antitumour metallocenes, in particular Cp2TiCl2 1, which is currently undergoing phase II clinical trials. The interactions of Cp2MoCl2 4 with four oligonucleotides were stud
APA, Harvard, Vancouver, ISO, and other styles
3

Gate, Ernest N. "Investigations on new antitumour agents." Thesis, Aston University, 1985. http://publications.aston.ac.uk/12512/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Skelton, Lorraine Ann. "Pyridyl quinazolines as potential antitumour agents." Thesis, Institute of Cancer Research (University Of London), 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.294789.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Shi, Dong-Fang. "The medicinal chemistry of antitumour benzazoles." Thesis, University of Nottingham, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.283645.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Langnel, David Antoine Fernand. "New synthetic routes to antitumour imidazotetrazines." Thesis, University of Nottingham, 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.311742.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shahbakhti, Hassan. "Structure/activity relationships of antitumour diazridinylquinones." Thesis, University of Salford, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.308289.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ayuko, Washington O. "Free radicals as potential antitumour agents." Thesis, Aston University, 1991. http://publications.aston.ac.uk/12521/.

Full text
Abstract:
The aim of this work was to use extremely low concentrations of free radical generating compounds as a 'catalyst' to trigger endogenous free radical chain reactions in the host and to selectively eliminate neoplastic cells in the host. To test the hypothesis, a number of free radical generating compounds were screened on several malignant cell lines in vitro to select model compounds that were used against tumour models in vivo. 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and its derivatives were selected at the model compounds for in vivo experiments in view of their high cytotoxic potency against s
APA, Harvard, Vancouver, ISO, and other styles
9

Horspool, Keith R. "Structure-activity studies on antitumour imidazotetrazinones." Thesis, Aston University, 1988. http://publications.aston.ac.uk/12550/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rafferty, Karen. "Novel organometallic compounds as potential antitumour agents." Thesis, University of Leeds, 2008. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.487773.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Antitumour"

1

Gielen, M., ed. Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

1938-, Gielen M., ed. Tin-based antitumour drugs. Springer-Verlag, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

V, Wilman Derry E., ed. The chemistry of antitumour agents. Blackie, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wilman, Derry E. V., ed. The Chemistry of Antitumour Agents. Springer Netherlands, 1990. http://dx.doi.org/10.1007/978-94-009-0397-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

V, Wilman Derry E., ed. The Chemistry of antitumour agents. Blackie, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gate, Ernest Nicholas. Investigations on new antitumour agents. University of Aston in Birmingham. Department of Pharmaceutical Sciences, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Shahbakhti, Hassan. Structure/activity relationships of antitumour diaziridinylquinones. University of Salford, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Horspool, Keith Ronald. Structure-activity studies on antitumour imidazotetrazionones. Aston University. Departmentof Pharmaceutical Sciences, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Blackman, Claire. Studies on carbinolamine-containing triazine antitumour agents. University of Portsmouth, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Secrett, Peter Clement. Orally active antitumour agents, patient compliance and clinical trials. Aston University Department of Pharmaceutical Sciences, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Antitumour"

1

Suarato, A. "Antitumour anthracyclines." In The Chemistry of Antitumour Agents. Springer Netherlands, 1990. http://dx.doi.org/10.1007/978-94-009-0397-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rees, R. C., and S. A. Ali. "Antitumour Lymphocyte Responses." In Immunological Aspects of Cancer. Springer US, 1985. http://dx.doi.org/10.1007/978-1-4613-2557-4_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Schiller, Erich. "Antitumour Drug Therapy." In Free Radicals and Inhalation Pathology. Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18619-6_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Keppler, B. K. "The Role of Non-Platinum Complexes in Cancer Therapy." In Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Crowe, Alan J. "Tin Compounds and their Potential as Pharmaceutical Agents." In Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Cardarelli, Nate F. "The Role of Tin Hormones in Senescence: A Hypothesis." In Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Duffield, J. R., C. R. Morris, D. M. Morrish, J. A. Vesey, and D. R. Williams. "The Speciation and Bioavailability of Tin in Biofluids." In Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Penninks, André H., Marianne Bol-Schoenmakers, and Willem Seinen. "Cellular interactions of organotin compounds in relation to their antitumor activity." In Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hennighausen, Gerhard, and Stanisław Szymaniec. "Selectivity of Antiproliferative Effects of Dialkyltin Compounds in Vitro and in Vivo." In Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Narayanan, V. L., M. Nasr, and K. D. Paull. "Computer Assisted Structure-Antileukemic Activity Correlations of Organotin Compounds and Initial Exploration of their Potential Anti-HIV Activity." In Tin-Based Antitumour Drugs. Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74191-3_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Antitumour"

1

Kopoleva, E. A., and A. Peltek. "DEVELOPING REDOX-SENSITIVE NANOPARTICLES BASED ON TRITHIOCYANURIC ACID FOR THE TARGET DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-91.

Full text
Abstract:
This research work is devoted to the developing of a method for the synthesis of trithiocyanuric acid (TTCA)-based nanoparticles as carriers of low molecular weight antitumour drugs. The presented work describes the method of synthesis of TTCA-based particles, their structural and morphological characterization, their sorption properties, as well as the study of the obtained nanoparticles as systems for in vitro delivery of antitumour drugs on 4T1 and A549 cell lines.
APA, Harvard, Vancouver, ISO, and other styles
2

Xuan Yuan, Defang Li, Hongmei Chen, et al. "Isoliquiritigen Enhances Antitumour Activity of Cyclophosphamid." In 2010 International Conference on Bioinformatics and Biomedical Technology. IEEE, 2010. http://dx.doi.org/10.1109/icbbt.2010.5478984.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Welchinskaya, Elena. "CHEMISTRY AND ANTITUMOUR ACTIVITY OF 5-BROMOURACILE’S DERIVATIVES." In CBU International Conference on Integration and Innovation in Science and Education. Central Bohemia University, 2013. http://dx.doi.org/10.12955/cbup.2013.45.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ivanenko, K. A., T. D. Lebedev, and V. S. Prasolov. "EFFECTIVE COMBINATIONS OF ANTITUMOUR DRUGS WITH MITHRAMYCIN A FOR LEUKAEMIA THERAPY." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-238.

Full text
Abstract:
Transcription factor Sp1 can regulate gene expression in the cells of some malignant diseases. In this study, we explored the possibility of combining the proposed inhibitor of the transcriptional activity of Sp1 (mithramycin A) with inhibitors of different classes in relation to human leukemia cell lines.
APA, Harvard, Vancouver, ISO, and other styles
5

Vanmeerbeek, Isaure, Stefan Naulaerts, Jenny Sprooten, et al. "894 Conserved immune inhibitory receptor-signaling in macrophages limits antitumour chemo-immunotherapy." In SITC 38th Annual Meeting (SITC 2023) Abstracts. BMJ Publishing Group Ltd, 2023. http://dx.doi.org/10.1136/jitc-2023-sitc2023.0894.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Jin, Xiaorong. "The structure of lentinan and its effects on immunomodulation, antitumour, and antiviral." In International Conference on Biological Engineering and Medical Science (ICBIOMed2022), edited by Gary Royle and Steven M. Lipkin. SPIE, 2023. http://dx.doi.org/10.1117/12.2669637.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Becker, Til J., Tamara Krajnović, Vuk Gordić, et al. "TETRAKIS(4-METHOXYBENZENE)TIN(IV) IMMOBILISED INTO MCM-41 AND SBA-15 MESOPOROUS NANOSTRUCTURES." In 17th International Conference on Fundamental and Applied Aspects of Physical Chemistry. Society of Physical Chemists of Serbia, 2024. https://doi.org/10.46793/phys.chem24i.285b.

Full text
Abstract:
Tetraaryltin(IV) compounds are suitable compounds to replace platinum-based chemotherapeutics since they provide promising in vitro results. To further decrease toxicity and side effects, passive drug targeting via nanostructures can be utilised, since tumour tissues provide the ability to accumulate bigger particles than healthy ones. In this study, tetrakis(4-methoxybenzene)tin(IV) (1) is immobilised in two mesoporous silica nanostructures (MCM-41|1 and SBA-15|1), which are synthesised and characterised herein. Employing MTT and CV assays, the antitumour activity of the organotin(IV) compoun
APA, Harvard, Vancouver, ISO, and other styles
8

Diez Fernandez, R., F. Fernandez Fraga, M. Moreno Garcia, and T. Molina Garcia. "4CPS-279 Cancer pain management approach considering potential drug interactions in patients receiving oral antitumour treatment." In 25th Anniversary EAHP Congress, Hospital Pharmacy 5.0 – the future of patient care, 23–28 March 2021. British Medical Journal Publishing Group, 2021. http://dx.doi.org/10.1136/ejhpharm-2021-eahpconf.111.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jacq, Xavier, Lisa Smith, Elaine Brown, et al. "Abstract 1823: AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1823.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Cheng, L., J. Wang, and R. Liu. "Abstract P1-04-01: A novel oncolytic herpes simplex virus, GD116, has enhanced antitumour efficacy in human breast cancer." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p1-04-01.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Antitumour"

1

Georgieva, Ani, Katerina Todorova, Ivan Iliev, et al. In Vitro Antitumour Activity of Hemocyanins Isolated fromHelix aspersaandHelix lucorumin Human Bladder Car cinoma Cells. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, 2021. http://dx.doi.org/10.7546/crabs.2021.09.10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wang, He, Jun Chen, Xiaoling Wang, and Jun Dang. Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.6.0052.

Full text
Abstract:
Review question / Objective: It remains unclear whether addition of immune checkpoint inhibitor (ICI) to neoadjuvant chemoradiotherapy (nCRT) or neoadjuvant chemotherapy (nCT) can increase antitumor efficacy in resectable esophageal cancer (EC). we performed the systematic review and meta-analysis to assess antitumor efficacy and safety of nICRT and nICT, and made a comparison with nCRT and nICT. We used pathological complete response (pCR) as the primary outcomes of interest. Condition being studied: Initial findings from a number of phase 1 or 2 trials have supported the tolerability and/or
APA, Harvard, Vancouver, ISO, and other styles
3

Conejo-Garcia, Jose R. Reprogramming Antitumor Immune Responses with microRNAs. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada585107.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Conejo-Garcia, Jose R. Reprogramming Antitumor Immune Responses with microRNAs. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada595676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Basu, Sayani. Monoclonal Antibody Therapy: A New Hope in Cancer Treatment. Natur Library, 2020. http://dx.doi.org/10.47496/nl.blog.14.

Full text
Abstract:
The remarkable specificity, high efficacy and the ability to elicit an antitumor response indicate that monoclonal antibody therapy offers promise in the treatment of malignancy and appears to be clinically relevant
APA, Harvard, Vancouver, ISO, and other styles
6

Rayhim, Rayhana, and Jeannie S. Strobl. Augmentation of the Differentiation Response to Antitumor Antimalarials. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada432050.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Hill, Ann. Vaccine Vector for Sustained High-Level Antitumor CTL Response. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada546083.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fenton, Bruce M. Potentiation of Prostate Cancer Radiotherapy Using Antiangiogenic and Antitumor Therapies. Defense Technical Information Center, 2007. http://dx.doi.org/10.21236/ada478113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Karnchanatat, Aphichart. L-Asparaginase from xylariaceous fungi and application in antitumor activity. Chulalongkorn University, 2010. https://doi.org/10.58837/chula.res.2010.75.

Full text
Abstract:
From 30 xylariaceus fungi isolates, ten were found to produce extracellular L-Asparaginase (ASNase) activity, with Xylaria feejeensis isolate XL001, yielding the highest level. The ASNase activity in the Czapek Dox medium of XL001 was highest with 2.0 g/L glucose and 10 g/L L-asparagine as the carbon, nitrogen sources, respectively. A 42.5 kDa ASNase was enriched 41.4-fold to apparent homogeneity from XL001 cluture media using 80% saturation ammonium sulfate precipitation, DEAE-cellulose anion exchange and Superdex-75 gel filtration chromatography, but at a final yield of only 2.2%, an optimal
APA, Harvard, Vancouver, ISO, and other styles
10

Li, Chun. Radiation-Induced Chemosensitization: Potentiation of Antitumor Activity of Polymer-Drug Conjugates. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada406209.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antitumour' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography